Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Actinium Pharmaceuticals, Inc. (OTC: ATNM).

Full DD Report for ATNM

Recent News from (OTC: ATNM)

Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development
- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and Johnson & Johnson   - Dr. Reddy will be focused on Actinium’s targ...
Source: GlobeNewswire
Date: April, 18 2018 07:30
Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting
- In vivo data to be presented via poster highlighting the ability of Actinium’s AWE Technology to yield increased cell killing power, survival benefit and a potential biobetter of daratumumab, a blockbuster CD38 targeted therapy for multiple myeloma  - Members of Actinium...
Source: GlobeNewswire
Date: April, 11 2018 07:30
Key events next week - healthcare
Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 06 2018 07:14
Blog Exposure - Actinium Announces Collaboration with Astellas Pharma
Stock Monitor: Auris Medical Holding Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ) ("Actinium"). If you want access to this report all you need to do is sign up n...
Source: ACCESSWIRE IA
Date: April, 02 2018 07:30
Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium's AWE Platform Technology
- Collaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents  -  Actinium to perform preclinical validation studies on novel Actinium Radio-Conjugates under this agreement ...
Source: GlobeNewswire
Date: March, 28 2018 08:00
Key events next week - healthcare (continued #1)
Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR ); Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS...
Source: SeekingAlpha
Date: March, 16 2018 10:26
Actinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare Conference
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 28 th Annual Oppenheimer Healthcare Conference being held on March 20-21, 2018, at The Wes...
Source: GlobeNewswire
Date: March, 15 2018 07:30
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or serious conditions with unmet medical need Dr. Rowlands to lead Actinium’s clinic...
Source: GlobeNewswire
Date: March, 14 2018 07:30
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
Clinical trial to be conducted by the Medical College of Wisconsin as an investigator initiated trial led by Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah  Combination trial expands addressable patient population for Actinium’s CD33 program into relapsed or refra...
Source: GlobeNewswire
Date: March, 13 2018 07:30
Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30 th Annual ROTH Conference being held on March 11-14, 2018 at the Ritz Carlton in Dana Po...
Source: GlobeNewswire
Date: March, 07 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-240.35050.33590.359810.3323468,415
2018-04-230.3750.35340.380.351,264,130
2018-04-220.38280.37530.38280.375564,739
2018-04-210.38280.37530.38280.375564,739
2018-04-200.38280.37530.38280.375564,739

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report.


About Actinium Pharmaceuticals, Inc. (OTC: ATNM)

Logo for Actinium Pharmaceuticals, Inc. (OTC: ATNM)

Actinium Pharmaceuticals, Inc. ATNM.OB is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium and bismuth and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company s lead radiopharmaceutical Iomab TM B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase clinical study of Iomab B in refractory and relapsed Acute Myeloid Leukemia AML patients over the age of with a primary endpoint of durable complete remission. The company s second program, Actimab A, is continuing its clinical development in a Phase / trial for newly diagnosed AML patients over the age of in a single arm multicenter trial.

 

 

 

Current Management

  • Kaushik Dave / CEO
  • Dragan Cicic / COO, Chief Med. Officer
  • Corey Sohmer / VP, Fin.
  • Sergio Traversa / CFO, Interim CFO
  • Sergio Traversa / NonExecutive Director
  • Kaushik Dave /

Current Share Structure

  • Market Cap: $31,282,022 - 03/20/2018
  • Authorized: 200,000,000 - 01/28/2014
  • Issue and Outstanding: 80,025,639 - 11/03/2017

 


Recent Filings from (OTC: ATNM)

Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 16 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (OTC: ATNM)

Daily Technical Chart for (OTC: ATNM)


Stay tuned for daily updates and more on (OTC: ATNM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ATNM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATNM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ATNM and does not buy, sell, or trade any shares of ATNM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us